These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 31356909)

  • 1. Progress in the development of antiplatelet agents: Focus on the targeted molecular pathway from bench to clinic.
    Xiang Q; Pang X; Liu Z; Yang G; Tao W; Pei Q; Cui Y
    Pharmacol Ther; 2019 Nov; 203():107393. PubMed ID: 31356909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The progress in the research of antiplatelet agents (1995-2017).
    Benimana O; Zhao L; Kong Y; Li Z; Xie Z
    Future Med Chem; 2017 Jun; 9(10):1087-1110. PubMed ID: 28632424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist.
    Mousa SA; Bozarth JM; Forsythe MS; Jackson SM; Leamy A; Diemer MM; Kapil RP; Knabb RM; Mayo MC; Pierce SK
    Circulation; 1994 Jan; 89(1):3-12. PubMed ID: 8281661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Antiplatelet Agents in Cardiovascular Disease.
    Tscharre M; Michelson AD; Gremmel T
    J Cardiovasc Pharmacol Ther; 2020 May; 25(3):191-200. PubMed ID: 31960728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Mechanisms of platelet activation and development of antiplatelet agents].
    Cazenave JP; Gachet C; Lanza F
    Arch Mal Coeur Vaiss; 1996 Nov; 89(11 Suppl):1501-6. PubMed ID: 9092410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New perspectives in antiplatelet therapy.
    Tello-Montoliu A; Jover E; Rivera J; Valdés M; Angiolillo DJ; Marín F
    Curr Med Chem; 2012; 19(3):406-27. PubMed ID: 22335515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The genetics of antiplatelet drug resistance.
    Feher G; Feher A; Pusch G; Lupkovics G; Szapary L; Papp E
    Clin Genet; 2009 Jan; 75(1):1-18. PubMed ID: 19067731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current and future antiplatelet therapies: emphasis on preserving haemostasis.
    McFadyen JD; Schaff M; Peter K
    Nat Rev Cardiol; 2018 Mar; 15(3):181-191. PubMed ID: 29297508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents.
    Natarajan A; Zaman AG; Marshall SM
    Diab Vasc Dis Res; 2008 Jun; 5(2):138-44. PubMed ID: 18537103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiplatelet therapies: platelet GPIIb/IIIa antagonists and beyond.
    Konstantopoulos K; Mousa SA
    Curr Opin Investig Drugs; 2001 Aug; 2(8):1086-92. PubMed ID: 11892918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet receptors as therapeutic targets: Past, present and future.
    Jamasbi J; Ayabe K; Goto S; Nieswandt B; Peter K; Siess W
    Thromb Haemost; 2017 Jun; 117(7):1249-1257. PubMed ID: 28597906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of a novel function-blocking antibody targeted against the platelet P2Y1 receptor.
    Karim ZA; Vemana HP; Alshbool FZ; Lin OA; Alshehri AM; Javaherizadeh P; Paez Espinosa EV; Khasawneh FT
    Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):637-44. PubMed ID: 25593131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiplatelet Therapy in Percutaneous Coronary Intervention.
    Fanaroff AC; Rao SV
    Interv Cardiol Clin; 2016 Apr; 5(2):221-237. PubMed ID: 28582206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective.
    Dyke CM
    Am Heart J; 1999 Oct; 138(4 Pt 2):307-16. PubMed ID: 10502236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current state and novel approaches of antiplatelet therapy.
    Metharom P; Berndt MC; Baker RI; Andrews RK
    Arterioscler Thromb Vasc Biol; 2015 Jun; 35(6):1327-38. PubMed ID: 25838432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P2Y
    Hensch NR; Karim ZA; Pineda J; Mercado N; Alshbool FZ; Khasawneh FT
    Biochem Biophys Res Commun; 2017 Nov; 493(2):1069-1074. PubMed ID: 28928091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel antiplatelet therapies for treatment of patients with ischemic heart disease: inhibitors of the platelet glycoprotein IIb/IIIa integrin receptor.
    Frishman WH; Burns B; Atac B; Alturk N; Altajar B; Lerrick K
    Am Heart J; 1995 Oct; 130(4):877-92. PubMed ID: 7572600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis.
    Jennings LK
    Thromb Haemost; 2009 Aug; 102(2):248-57. PubMed ID: 19652875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiplatelet therapy with glycoprotein IIb/IIIa receptor inhibitors and other novel agents.
    Schafer AI
    Tex Heart Inst J; 1997; 24(2):90-6. PubMed ID: 9205981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New targets for antithrombotic drugs.
    Thiagarajan P
    Am J Cardiovasc Drugs; 2002; 2(4):227-35. PubMed ID: 14727968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.